Generation of Recombinant SARS-CoV-2 Using a Bacterial Artificial Chromosome.
COVID-19
SARS-CoV-2
bacterial artificial chromosome
coronavirus
infectious clone
reverse genetics
virus rescue
Journal
Current protocols in microbiology
ISSN: 1934-8533
Titre abrégé: Curr Protoc Microbiol
Pays: United States
ID NLM: 101257113
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
13
10
2020
pubmed:
14
10
2020
medline:
28
10
2020
Statut:
ppublish
Résumé
SARS-CoV-2, the causative agent of COVID-19, has been responsible for a million deaths worldwide as of September 2020. At the time of this writing, there are no available US FDA-approved therapeutics for the treatment of SARS-CoV-2 infection. Here, we describe a detailed protocol to generate recombinant (r)SARS-CoV-2 using reverse-genetics approaches based on the use of a bacterial artificial chromosome (BAC). This method will allow the production of mutant rSARS-CoV-2-which is necessary for understanding the function of viral proteins, viral pathogenesis and/or transmission, and interactions at the virus-host interface-and attenuated SARS-CoV-2 to facilitate the discovery of effective countermeasures to control the ongoing SARS-CoV-2 pandemic. © 2020 Wiley Periodicals LLC. Basic Protocol: Generation of recombinant SARS-CoV-2 using a bacterial artificial chromosome Support Protocol: Validation and characterization of rSARS-CoV-2.
Identifiants
pubmed: 33048448
doi: 10.1002/cpmc.126
pmc: PMC7646048
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e126Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Curr Protoc Microbiol. 2020 Dec;59(1):e126
pubmed: 33048448
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Virology. 2012 Dec 5;434(1):129-36
pubmed: 23062737
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
J Vis Exp. 2019 Jun 24;(148):
pubmed: 31282877
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
mBio. 2012 Nov 20;3(6):
pubmed: 23170002
JCI Insight. 2020 Oct 2;5(19):
pubmed: 32841215
Sci Rep. 2020 Jan 16;10(1):512
pubmed: 31949262
Nature. 2020 Jun;582(7813):561-565
pubmed: 32365353
Lancet Infect Dis. 2020 Sep;20(9):e238-e244
pubmed: 32628905
J Virol. 2006 Nov;80(21):10900-6
pubmed: 16928748
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
Curr Top Microbiol Immunol. 2005;287:57-94
pubmed: 15609509
J Gen Virol. 2020 Sep;101(9):925-940
pubmed: 32568027
Travel Med Infect Dis. 2019 May - Jun;29:48-50
pubmed: 30872071
mBio. 2020 Sep 25;11(5):
pubmed: 32978313
J Virol. 2011 Mar;85(6):2927-41
pubmed: 21228244
Epidemiol Infect. 2019 Jan;147:e198
pubmed: 31364519
Lancet. 2003 Apr 19;361(9366):1319-25
pubmed: 12711465
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930